Publications en collaboration avec des chercheurs de Hospital Universitario Virgen de la Victoria (11)

2021

  1. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma

    Scientific Reports, Vol. 11, Núm. 1

  2. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus

    Pancreatology, Vol. 21, Núm. 1, pp. 215-223

2019

  1. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group

    Hematological Oncology, Vol. 37, Núm. 2, pp. 143-150

  2. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

    PLoS ONE, Vol. 14, Núm. 2

2018

  1. Efficacy and safety of vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii476

  2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

2017

  1. Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 17, Núm. 3, pp. 186-191

  2. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group

    Cancer, Vol. 123, Núm. 19, pp. 3709-3716

2014

  1. High serum levels of vascular endothelial growth factor-C have a positive impact on outcome of patients with advanced diffuse large B cell lymphoma

    Leukemia and Lymphoma

  2. Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis

    Haematologica

2013

  1. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

    European Journal of Cancer, Vol. 49, Núm. 18, pp. 3780-3787